113
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms

ORCID Icon, , , , , , , , , , , & show all
Pages 2347-2350 | Received 29 Jul 2023, Accepted 31 Aug 2023, Published online: 07 Sep 2023
 

Disclosure statement

Dr. Gaulin reports personal fees from DeciBio, personal fees from ADC Therapeutics, outside the submitted work. Dr. Craig has nothing to disclose. Dr. Fortin Ensign has nothing to disclose. Dr. Robetorye has nothing to disclose. Dr. Gibson has nothing to disclose. Dr. Kelemen has nothing to disclose. Dr. Khera has nothing to disclose. Dr. Leis has nothing to disclose. Dr. Tsang has nothing to disclose. Dr. Rosenthal has nothing to disclose. Dr. Munoz reports grants and personal fees from Pharmacyclics/Abbvie, grants and personal fees from Bayer, grants and personal fees from Gilead/Kite Pharma, personal fees from Pfizer, grants and personal fees from Janssen, personal fees from Juno/Celgene, personal fees from BMS, personal fees from Kyowa, personal fees from Alexion, personal fees from Fosun kite, personal fees from lnnovent, grants and personal fees from Seattle Genetics, personal fees from Debiopharm, personal fees from Karyopharm, personal fees from Genmab, personal fees from ADC Therapeutics, personal fees from Epizyme, personal fees from BeiGene, personal fees from Servier, personal fees from Novartis, personal fees from Morphosys/lncyte, personal fees from Secura Bio, personal fees from TG Therapeutics, personal fees from MEI, personal fees from Lilly/Loxo, grants from Celgene, grants from Merck, grants from Portola, grants from lncyte, grants from Genentech, grants from Millennium, personal fees from Targeted Oncology, personal fees from OncView, personal fees from Curio, personal fees from Physicians’ Education Resource, personal fees from Pharmacyclics/Janssen, personal fees from Acrotech/Aurobindo, personal fees from Pharmacyclics, personal fees from Verastem, personal fees from AstraZeneca, personal fees from Celgene/BMS, personal fees from Genentech/Roche, outside the submitted work. Dr. Palmer has nothing to disclose. Dr. Hilal has nothing to disclose.

Data availability statement

The data that support the findings of this study are available upon reasonable request.

Additional information

Funding

This research received no external funding.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.